Drug maker Valeant in talks on $13 billion Actavis buy: source
By Reuters
Posted: April 27, 2013 - 1:30 pm ET
Tags:
Canada's largest listed drug maker, Valeant Pharmaceuticals International Inc, is in talks to buy generic drugmaker Actavis Inc for more than $13 billion, a person familiar with the situation told Reuters on Friday night.
Switch to the new Modern Healthcare Daily News app
For the best experience of ModernHealthcare.com on your iPad, switch to the new Modern Healthcare app — it's optimized for your device but there is no need to download.